ArticleFrontiers in immunology2015
Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype.
Article in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 37 citations in OpenAlex.
- Influenza antibody breadth and effector functions are immune correlates from acquisition of pandemic infection of children.Nature communications · 2024Trial
- Charge-driven antiviral responses enhance autoreactivity in severe COVID-19.Research square · 2026Article
- Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses.Scientific reports · 2025Article
- DNA and protein-generated chimeric molecules for delivery of influenza viral epitopes in mouse and humanized NSG transfer models.Human vaccines & immunotherapeutics · 2024Review
- A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine.NPJ vaccines · 2022Article
- Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses.NPJ vaccines · 2021Article
- Review
- More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation.Viruses · 2021Review
- Review
- Targeting the Host Response: Can We Manipulate Extracellular Matrix Metalloproteinase Activity to Improve Influenza Virus Infection Outcomes?Frontiers in molecular biosciences · 2021Review
- Repeated influenza vaccination provides cumulative protection from distinct H3N2 viruses.Clinical & translational immunology · 2021Article
- Influenza Hemagglutinin Head Domain Mimicry by Rational Design.The protein journal · 2020Article
- Influenza Hemagglutinin Structures and Antibody Recognition.Cold Spring Harbor perspectives in medicine · 2020Review
- Review
- A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.Frontiers in immunology · 2020Article
- Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults.Clinical & translational immunology · 2020Article
- Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus.Viruses · 2019Review
- Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens.The Journal of infectious diseases · 2019Article
- Article
- Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seasonal epidemics caused by influenza A (H1 and H3 subtypes) and B viruses are a major global health threat. The traditional, trivalent influenza vaccines have limited efficacy because of rapid antigenic evolution of the circulating viruses. This antigenic variability mediates viral escape from the host immune responses, necessitating annual vaccine updates. Influenza vaccines elicit a protective antibody response, primarily targeting the viral surface glycoprotein hemagglutinin (HA). However, the predominant humoral response is against the hypervariable head domain of HA, thereby restricting the breadth of protection. In contrast, the conserved, subdominant stem domain of HA is a potential "universal" vaccine candidate. We designed an HA stem-fragment immunogen from the 1968 pandemic H3N2 strain (A/Hong Kong/1/68) guided by a comprehensive H3 HA sequence conservation analysis. The biophysical properties of the designed immunogen were further improved by C-terminal fusion of a trimerization motif, "isoleucine-zipper", or "foldon". These immunogens elicited cross-reactive, antiviral antibodies and conferred partial protection against a lethal, homologous HK68 virus challenge in vivo. Furthermore, bacterial expression of these immunogens is economical and facilitates rapid scale-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.